clopidogrel has been researched along with betadex in 3 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (33.33) | 29.6817 |
| 2010's | 2 (66.67) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Agbaba, D; Besović, Z; Ivković, B; Marković, S; Nikolic, K | 1 |
| Adams, MP; Cooper, WD; Cushing, DJ; Kowey, PR; Machatha, S; Mosher, GL; Souney, PF; Zhang, B | 1 |
| Anzaha, G; Brugier, D; Collet, JP; Funck-Brentano, C; Galier, S; Gallois, V; Guilloux, E; He, K; Hu, MY; Hulot, JS; Montalescot, G; Nicolas, N; Prats, J; Salem, JE; Silvain, J | 1 |
2 trial(s) available for clopidogrel and betadex
| Article | Year |
|---|---|
Pharmacokinetics and platelet aggregation inhibitory effects of a novel intravenous formulation of clopidogrel in humans.
Topics: Adult; beta-Cyclodextrins; Biotransformation; Clopidogrel; Dose-Response Relationship, Drug; Drug Compounding; Excipients; Female; Half-Life; Humans; Infusions, Intravenous; Injections, Intravenous; Male; Metabolic Clearance Rate; Middle Aged; Platelet Aggregation; Platelet Aggregation Inhibitors; Prodrugs; Purinergic P2Y Receptor Antagonists; Ticlopidine | 2012 |
Intravenous Clopidogrel (MDCO-157) Compared with Oral Clopidogrel: The Randomized Cross-Over AMPHORE Study.
Topics: Administration, Oral; Adult; beta-Cyclodextrins; Clopidogrel; Cross-Over Studies; Dose-Response Relationship, Drug; Female; Flow Cytometry; Humans; Infusions, Intravenous; Male; Platelet Aggregation; Platelet Aggregation Inhibitors; Purinergic P2Y Receptor Antagonists; Ticlopidine; Young Adult | 2016 |
1 other study(ies) available for clopidogrel and betadex
| Article | Year |
|---|---|
A validated enantiospecific method for determination and purity assay of clopridogrel.
Topics: beta-Cyclodextrins; Biological Assay; Calibration; Chromatography, High Pressure Liquid; Clopidogrel; Computational Biology; Drug Contamination; Guidelines as Topic; Hydrogen-Ion Concentration; Models, Molecular; Molecular Structure; Platelet Aggregation Inhibitors; Reference Standards; Reproducibility of Results; Spectrophotometry, Ultraviolet; Stereoisomerism; Structure-Activity Relationship; Tablets; Technology, Pharmaceutical; Thermodynamics; Ticlopidine | 2009 |